A5083615995- Cholangiocarcinoma and Gallbladder Cancer Studies
- Advanced Breast Cancer Therapies
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Pediatric Hepatobiliary Diseases and Treatments
- Bladder and Urothelial Cancer Treatments
- Gallbladder and Bile Duct Disorders
- Reproductive Biology and Fertility
- Cancer Mechanisms and Therapy
- Ocular Oncology and Treatments
- RNA modifications and cancer
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- Cancer Research and Treatments
- Cutaneous Melanoma Detection and Management
- Drug Transport and Resistance Mechanisms
- Ovarian cancer diagnosis and treatment
- Renal and related cancers
- Genetic factors in colorectal cancer
- Nanoplatforms for cancer theranostics
- Cancer Cells and Metastasis
Princess Margaret Cancer Centre
2022-2025
University of Toronto
2024-2025
CancerCare Manitoba
2025
University of Manitoba
2025
University Health Network
2023-2025
Molecular Medicine Ireland
2024
Royal College of Surgeons in Ireland
2020-2023
St. Vincent's University Hospital
2021
Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (PI3K/mTOR dual inhibitor) and PD0325901 (MEK1/2 in colorectal cancer (CRC), however single agent therapeutics are often limited by development resistance.We compared anti-proliferative effects combination five CRC cell lines with varying mutational background tested their combinations on total phosphoprotein levels signaling pathway proteins.The was superior to PD0325901. The had synergistic all [CI...
The IMbrave150 trial established atezolizumab with bevacizumab (A+B) as standard care for hepatocellular carcinoma (HCC), recommending an esophagogastroduodenoscopy (EGD) within 6 months of treatment initiation to prevent bleeding from esophagogastric varices. necessity mandatory EGD all patients remains unclear. We retrospectively analyzed 112 HCC treated A+B at five Canadian cancer centers July 1, 2020, August 31, 2022. was the first-line therapy 90% patients, median overall survival 20.3...
The IMbrave150 trial established atezolizumab with bevacizumab (A+B) as standard care for hepatocellular carcinoma (HCC), recommending an esophagogastroduodenoscopy (EGD) within 6 months of treatment initiation to prevent bleeding from esophagogastric varices. necessity mandatory EGD all patients remains unclear. We retrospectively analyzed 112 HCC treated A+B at five Canadian cancer centers 1 July 2020 31 August 2022. was the first-line therapy 90% patients, median overall survival 20.3 and...
Abstract Isocitrate dehydrogenase (IDH) enzymes catalyze the decarboxylation of isocitrate to alpha-ketoglutarate (αKG). IDH1/2 mutations preferentially convert αKG R-2-hydroxyglutarate (R2HG), resulting in R2HG accumulation tumor tissues. We investigated circulating 2-hydroxyglutate (2HG) as potential biomarkers for patients with IDH-mutant (IDHmt) cholangiocarcinoma (CCA). and S-2-hydroxyglutarate (S2HG) levels blood tissues were analyzed a discovery cohort IDHmt glioma CCA. Results...
The incidence of melanoma among young adults has risen, yet mortality declined annually since the introduction immune checkpoint inhibitors (ICI). utilization peri-operative ICI significantly altered treatment landscape in melanoma, with PD-1 showing promising efficacy improving relapse-free survival rates high-risk stage II-III disease. With increasing use ICI, secondary concerns have emerged regarding impact cancer drugs on fertility and reproductive health child-bearing women, especially...
The CDK4/6 inhibitor Ribociclib has shown limited efficacy as a monotherapy in colorectal cancer (CRC). However, combining with targeted therapies could present viable strategy for treating CRC. This study evaluated the combination of and PI3K Alpelisib across four distinct cell lines representing different mutational statuses (
3049 Background: Mutations in IDH1/2 genes are common low-grade glioma (GM) and occur approximately 20% of intrahepatic cholangiocarcinoma (ICCA). Mutant IDHs leads to preferential accumulation the R-relative (R2HG) S-enantiomer (S2HG) 2HG. We investigated utility circulating R2HG, total R2HG+S2HG (tRS) ratio R2HG/S2HG (rRS) as biomarkers GM ICCA patients (pts). Methods: Blood tumor tissues samples were obtained from pts with IDH1/2-mutant ICCA. IDH mutation was confirmed by either...
179 Background: Combinative inhibitors with multiple actions to target downstream effectors are good strategy reduce resistance occurrence. This is a preclinical study evaluate efficacy of Palbociclib (P; CDK4/6 inhibitor) in combination either Gedatolisib (G; P13K/mTOR dual inhibitors) or PD0325901 (PD; MEK 1/2 CRC cell models. Methods: Five lines hot-spots mutations PI3K and MAPK pathways genes used. Cell growth assay used antiproliferative response P, G PD alone combination. RPPA clarify...
e21585 Background: The treatment of MUM remains highly unsatisfactory. Single agent ICI produce low response rates. Two recent phase II trials combination Ipilimumab and Nivolumab yielded rates 12% 18%. We report the long-term survival results patients (pts) treated with in our institution. Methods: conducted a retrospective analysis all pts diagnosis St Vincent’s University Hospital. Overall (OS) was calculated from time first systemic relapse to death or latest follow-up. One-way ANOVA is...
Abstract Background: Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (PI3K/mTOR dual inhibitor) and PD0325901 (MEK1/2 in colorectal cancer (CRC), however single agent therapeutics are often limited by resistance. The main purpose this vitro study is to comprehensively test two drug combinations [Palbociclib with (P+G) (P+PD)] determine most synergistic combination for clinical development. Methods: We compared anti-proliferative effects both five CRC...